Uncategorized Archives - BioMedWire (BMW)

TuesdayJul 29, 2025 1:45 pm

Why Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF) Is ‘One to Watch’

Izotropic is the only commercial entity with exclusive global rights to the Breast CT technology developed at UC Davis. The company has secured regulatory alignment with the FDA and is preparing for a pivotal U.S. clinical trial. IzoView offers a proprietary, patient-centric alternative to mammography for dense breast tissue imaging. A comprehensive business and financial plan supports execution across clinical, regulatory, and commercial milestones. Awareness campaigns, including breastct.com and a company podcast, are primed to drive engagement and investor visibility. Izotropic (CSE: IZO) (OTCQB: IZOZF) is a medical device company advancing dedicated imaging solutions to improve the screening, diagnosis, and treatment of…

MondayJul 28, 2025 9:00 am

Clene Inc. (NASDAQ: CLNN) Offers Investors a Compelling Entry into the Growing ALS Market with Key FDA Milestones for Lead Drug Candidate

Clene is progressing toward a potential FDA accelerated approval for its ALS (Amyotrophic Lateral Sclerosis) drug CNM-Au8® in 2026, a market that is expected to reach $1.3 billion by 2034 with significant unmet need. Clene’s technology targets mitochondrial dysfunction, a novel approach to neurodegenerative diseases, and key FDA meetings in the coming months of 2025 could be major valuation catalysts for investors. Biomarker and survival data from over 150 patients will be critical to the company’s regulatory case and expects important NfL data in the fourth quarter of 2025. Clene is preparing to initiate a confirmatory Phase 3 ALS trial…

ThursdayJul 24, 2025 12:00 pm

Soligenix Inc. (NASDAQ: SNGX) Pioneering Oral Mucositis Treatment with Novel Therapeutic, Promising Study Results

Severe oral mucositis (“SOM”) often necessitates hospitalization, opioid pain management and feeding tube placement, substantially lowering quality of life. Soligenix has taken on this challenge with SGX942, a treatment aimed at reducing tissue inflammation, promoting healing and supporting immune response. The company is in the process of analyzing combined phase 2 and 3 datasets to design a second phase 3 study. Oral mucositis, a debilitating side effect of cancer therapy with no FDA-approved treatment, continues to wreak havoc on patients undergoing cancer care, prompting an urgent need for effective interventions. Soligenix (NASDAQ: SNGX) is stepping forward with SGX942, a novel therapeutic aimed…

FridayJul 18, 2025 9:00 am

Soligenix Inc. (NASDAQ: SNGX) Reports Strong Results in ‘Real-World’ Trial

Recent data indicates Soligenix’s HyBryte(TM) is showing promising treatment success in early-stage cutaneous T-cell lymphoma. “With limited treatment options, especially in the early stages of their disease, CTCL patients are often searching for alternative treatments,” leading investigator states. No new FDA-approved, skin-directed therapies have been introduced in more than a decade, and conventional options carry risks. Soligenix (NASDAQ: SNGX) is reporting encouraging interim outcomes from the ongoing investigator-initiated study (“IIS”) of its HyBryte(TM) (synthetic hypericin) program, under the direction of Ellen Kim, MD, director of the Penn Cutaneous Lymphoma Program. Kim is a leading enroller in Soligenix’s phase 3 FLASH study and…

FridayJul 11, 2025 10:00 am

Dutch Startup Develops Highly Sensitive Field Test for Infectious Diseases

Spotlight Diagnostics, a startup based in Eindhoven, Netherlands, is developing a test kit that will enable personnel to rapidly test for infectious diseases without requiring lab facilities. The kit targets infectious diseases like malaria, Chlamydia, gonorrhea and others that take a huge toll on human life. For example, malaria claims at least 600,000 lives globally each year, with most of these fatalities happening in low-income countries. Sub-Saharan Africa accounts for approximately 95% of this annual toll. The new test is intended to facilitate rapid diagnostics outside a lab in resource-constrained settings. In low-income countries, healthcare workers often administer treatment without…

ThursdayJul 10, 2025 9:00 am

New Study Suggests Concussions Could Lead to Higher Risks of Brain Cancer

A new study that has been published in JAMA Network has found that military veterans that sustained traumatic brain injuries (TBIs) had an elevated risk of developing cancerous brain tumors. Doctor Ian Stewart, who led this breakthrough study, explains that his team found that veterans that sustained moderate or severe TBIs had their likelihood of developing brain cancer increase by 90%. Glioblastoma, or GBM, is the most common type of brain cancer, and fatalities from this cancer are high. On average, individuals diagnosed with this type of cancer survive for 14 months only. While this link between TBIs and GBM…

TuesdayJul 08, 2025 9:00 am

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Subsidiary to Acquire 49% Stake in Prominent Florida Neuropsychiatry Clinic

The acquisition of Cohen and Associates, a respected interventional psychiatry practice, by NRx subsidiary HOPE Therapeutics, is expected to be immediately accretive to revenue and EBITDA. Cohen, serving the Sarasota-Bradenton area in Florida, specializes in treatments, including ketamine and TMS, for mood disorders, PTSD, and suicidal depression. HOPE Therapeutics is expanding toward a target of 30 clinics with a $100 million run rate by the end of 2025. NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, and its wholly-owned subsidiary HOPE Therapeutics, Inc., a multi-site clinical care delivery organization, recently signed a binding letter of intent to acquire a 49%…

MondayJul 07, 2025 11:50 am

Clene Inc. (NASDAQ: CLNN) to Conduct Neurofilament Biomarker Analysis for CNM-Au8(R) in ALS in Early Q4 2025

The FDA offered supportive feedback on Clene’s proposed statistical analysis plan during a recent Type C meeting. The neurofilament biomarker analysis results could support an accelerated approval submission for CNM-Au8 later in 2025. Clene has two additional FDA meetings scheduled in Q3 2025 to discuss ALS survival data and its MS program. Nearly 200 ALS patients are participating in the NIH-sponsored Expanded Access Program for CNM-Au8. The analysis aims to validate the neuroprotective effects shown in previous HEALEY Platform Trial results. Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial…

ThursdayJul 03, 2025 11:15 am

Nutriband Inc. (NASDAQ: NTRB) Added to Four Key Indexes, Rethinking Opioid Safety in a Time of Crisis

Nutriband and Kindeva have completed commercial-scale manufacturing for AVERSA(TM) Fentanyl, a major milestone in the path to FDA approval Updated analyst report raises NTRB’s price target to $15.00 and reiterates an Outperform rating, citing favorable trial pathway and strong execution Aversa abuse-deterrent tech is protected by international patents and may address a global unmet need in safe pain management NTRB boosting their profile and credibility with its recent membership to the Russel Indexes The opioid crisis remains one of the most pressing public health challenges of our time. While synthetic opioids like fentanyl play a crucial role in managing severe…

WednesdayJul 02, 2025 9:45 am

Adageis: An AI-Powered Advocate for Healthcare Providers

Adageis, a company offering a powerful and patented AI-centric software solution, remains committed to streamlining the healthcare sector, making it easier for providers to meet their financial goals It works with over 90 Electronic Health Record platforms, an unrivalled level of access that gives its users actionable insights at the point of care The company covers over 260,000 patient lives, and looks to double that to 580,000, achieving its $100,000 monthly recurring revenue target Adageis, a company offering powerful and patented AI-based software, provides flexible healthcare and related software solutions for providers and healthcare systems. The company remains committed to…